Sensible Biotechnologies: Engineering cells for scalable mRNA medicines.
Sensible Biotechnologies was founded with the mission to revolutionize the field of mRNA therapeutics by addressing critical manufacturing challenges. The company envisions a future where living cells are engineered to function as efficient factories, producing abundant, highly stable, and non-immunogenic mRNA. Their core product focuses on scalable and cost-effective mRNA production, which is crucial for advancing the next generation of mRNA-based medicines. Sensible Biotechnologies targets the biopharmaceutical market, aiming to enhance the development and accessibility of mRNA therapeutics.
Notable figures affiliated with Sensible Biotechnologies include leading experts in biotechnology and pharmaceutical sciences. The company has attracted significant interest from investors focused on innovative healthcare solutions. Key achievements include breakthroughs in cell engineering techniques that have demonstrated the potential for scalable mRNA production. Sensible Biotechnologies' impact lies in its ability to potentially lower the costs and increase the availability of mRNA medicines, thereby accelerating the development of treatments for various diseases.
Companies similar to Sensible Biotechnologies include Cisterna Biologics, Rnaimmune, ParcelBio and Vernal Biosciences.
Sensible Biotechnologies was founded in 2021.
Sensible Biotechnologies' headquarters is located in Bratislava, Bratislava Region, SK.
Sensible Biotechnologies' most recent funding round was for $4.2M (USD) in April 2023.
As of Apr 6, 2023, Sensible Biotechnologies has raised a total of $4.3M (USD).
Sensible Biotechnologies has 17 employees as of Mar 4, 2024.
ParcelBio
parcelbio.com
